Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Processa Pharmaceuticals, Inc.PCSA · Entity 8210 | Director · Pres. Research & Development | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Processa Pharmaceuticals, Inc.
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,729 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Purchase · Acquired 2,531 · Balance 21,729 |
| Common StockSEC Table I · non-derivative | IndirectBy Young-Plaisance Revocable Trust | 1,242 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,242 |
| Common StockSEC Table I · non-derivative | IndirectBy Family Entities | 432 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 432 |
| Common StockSEC Table I · non-derivative | IndirectBy CorLyst, LLC | 1,009 |
Reported balance
Holding disclosure · report date 2026-06-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,009 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:16 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,531 | $1.93 | $4,884.83 |
DisclosureSEC source: 0000897069-26-001476 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,729 Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:24 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 2,067 | $2.22 | $4,588.74 |
DisclosureSEC source: 0000897069-26-001414 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,198 Read SEC document |
| May 29, 2026 Filed Jun 1, 2026 21:01 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,786 | $2.57 | $4,590.02 |
DisclosureSEC source: 0000897069-26-001295 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,131 Read SEC document |
| May 15, 2026 Filed May 19, 2026 22:04 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,545 | $2.97 | $4,588.65 |
DisclosureSEC source: 0000897069-26-001184 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,345 F1 · balance_after: Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 13 shares. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:39 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,706 | $2.69 | $4,589.14 |
DisclosureSEC source: 0000897069-26-001010 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,813 Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:55 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,545 | $2.97 | $4,588.65 |
DisclosureSEC source: 0000897069-26-000912 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,107 Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 21:20 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 1,810 | $2.54 | $4,588.35 |
DisclosureSEC source: 0000897069-26-000756 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,562 Read SEC document |
| January 01, 2026 Filed Feb 4, 2026 22:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock Units · Derivative | 49 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000224 · form4.xml · derivative · entry 5 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. Read SEC document |
| January 01, 2026 Filed Feb 4, 2026 22:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 49 | $0.00 | $0.00 |
DisclosureSEC source: 0000897069-26-000224 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:25 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantStock Options (Right to Buy) · Derivative | 333,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0000897069-25-001545 · form4.xml · derivative · entry 2 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,000 Underlying: Common Stock · 333,000 shares Expires not disclosed F2 · derivative.exercise_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. F2 · derivative.expiration_date: Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:25 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 111,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001545 · form4.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,000 Underlying: Common Stock · 111,000 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:28 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 1,813,133 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-25-001215 · form4.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,821,016 Underlying: Common Stock · 1,813,133 shares Expires not disclosed F1 · shares: Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ("Omnibus Plan"), of which 1,790,833 shares are subject to stockholder approval of the revised Omnibus Plan. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028. Read SEC document |
| April 01, 2025 Filed Apr 11, 2025 21:16 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 5,345 | $0.41 | $2,202.14 |
DisclosureSEC source: 0000897069-25-000787 · form4.xml · nonDerivative · entry 2 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,332 Read SEC document |
| April 01, 2025 Filed Apr 11, 2025 21:16 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 17,272 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-25-000787 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| January 29, 2025 Filed Feb 18, 2025 22:57 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantWarrants · Derivative | 62,250 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000897069-25-000294 · form4.xml · derivative · entry 6 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,250 Underlying: Common Stock · 62,250 shares Expires 2030-01-29 Read SEC document |
| January 29, 2025 Filed Feb 18, 2025 22:57 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantWarrants · Derivative | 124,500 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000897069-25-000294 · form4.xml · derivative · entry 5 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,500 Underlying: Common Stock · 124,500 shares Expires 2030-01-29 Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 21:24 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 124,500 | $0.80 | $99,288.75 |
DisclosureSEC source: 0000897069-25-000132 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,405 Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 282 | $1.71 | $482.22 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · nonDerivative · entry 4 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,905 Read SEC document |
| July 10, 2024 Filed Aug 2, 2024 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 644 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · nonDerivative · entry 3 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 404 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · derivative · entry 11 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,155 Underlying: Common Stock · 404 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 404 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · derivative · entry 10 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,751 Underlying: Common Stock · 404 shares Expires not disclosed F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 2,425 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · derivative · entry 9 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,347 Underlying: Common Stock · 2,425 shares Expires not disclosed F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027. Read SEC document |
| June 28, 2024 Filed Aug 2, 2024 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 3,233 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · derivative · entry 8 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,922 Underlying: Common Stock · 3,233 shares Expires not disclosed F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right receive one share of the Issuer's common stock, following its vesting on January 1, 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right receive one share of the Issuer's common stock, following its vesting on January 1, 2025. Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 518 | $2.79 | $1,445.22 |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · nonDerivative · entry 2 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,543 Read SEC document |
| April 05, 2024 Filed Aug 2, 2024 21:09 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-001606 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:30 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 21,000 | $2.45 | $51,525.60 |
DisclosureSEC source: 0000897069-24-000269 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,387 Read SEC document |
| February 06, 2024 Filed Feb 7, 2024 21:22 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 20,000 | $2.53 | $50,504.00 |
DisclosureSEC source: 0000897069-24-000253 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,387 F1 · ownership.direct: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 21:01 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionRestricted Stock Units · Derivative | 1,675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000897069-24-000925 · form4.xml · derivative · entry 6 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,333 Underlying: Common Stock · 1,675 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Distribution of vested restricted shares. F1 · derivative.expiration_date: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 21:01 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 518 | $2.79 | $1,445.22 |
DisclosureSEC source: 0000897069-24-000925 · form4.xml · nonDerivative · entry 2 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,544 F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 01, 2024 Filed Apr 12, 2024 21:01 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 1,675 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000897069-24-000925 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Distribution of vested restricted shares. F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| October 12, 2023 Filed Oct 12, 2023 21:54 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 155,277 | $0.29 | $45,030.33 |
DisclosureSEC source: 0000897069-23-001460 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 767,701 Read SEC document |
| October 10, 2023 Filed Oct 10, 2023 21:03 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 142,000 | $0.24 | $34,080.00 |
DisclosureSEC source: 0000897069-23-001444 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · Pres. Research & Development · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 612,424 Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 20:31 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 40,000 | $0.80 | $32,000.00 |
DisclosureSEC source: 0000897069-23-000716 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 470,424 Read SEC document |
| April 14, 2023 Filed Apr 14, 2023 22:16 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 20,000 | $0.55 | $10,998.00 |
DisclosureSEC source: 0000897069-23-000278 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,424 Read SEC document |
| April 13, 2023 Filed Apr 13, 2023 20:51 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 20,000 | $0.48 | $9,600.00 |
DisclosureSEC source: 0000897069-23-000269 · form4.xml · nonDerivative · entry 3 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 410,424 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.51, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| April 12, 2023 Filed Apr 13, 2023 20:51 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 20,000 | $0.45 | $9,000.00 |
DisclosureSEC source: 0000897069-23-000269 · form4.xml · nonDerivative · entry 2 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,424 Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 20:51 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | PurchaseCommon Stock | 20,000 | $0.52 | $10,400.00 |
DisclosureSEC source: 0000897069-23-000269 · form4.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,424 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.49 to $0.53, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| February 09, 2023 Filed Feb 10, 2023 22:04 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantCommon Stock | 18,750 | $0.80 | $15,000.00 |
DisclosureSEC source: 0001567619-23-002398 · doc1.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,424 Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:39 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 24,030 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000321 · doc1.xml · derivative · entry 2 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,373 Underlying: Common Stock · 24,030 shares Expires not disclosed F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the issuer's common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death. F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the issuer's common stock, following its vesting of one-third on 01/01/24? 01/01/25 and 01/01/26, upon the earlier of termination of employment? the third anniversary of the award date? a change in control, or the reporting persons death. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:39 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 25,350 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000321 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,343 Underlying: Common Stock · 25,350 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the lessee's common stock upon the earliest of termination of employment, the third anniversary of the award date, a change of control, or the reporting person's death. These restricted stock units vest on date of grant. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the lessee's common stock upon the earliest of termination of employment, the third anniversary of the award date, a change of control, or the reporting person's death. These restricted stock units vest on date of grant. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 20:48 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 25,350 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-018056 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 374,993 Underlying: Common Stock · 25,350 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the lessee's common stock upon the earliest of termination of employment, the third anniversary of the award date, a change of control, or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the lessee's common stock upon the earliest of termination of employment, the third anniversary of the award date, a change of control, or the reporting person's death. Read SEC document |
| August 16, 2022 Filed Aug 23, 2022 20:30 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GiftCommon Stock | 9,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-016597 · doc1.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,784 Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:26 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Tax withholdingCommon Stock | 2,531 | $3.17 | $8,023.27 |
DisclosureSEC source: 0001567619-22-015306 · doc1.xml · nonDerivative · entry 2 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 387,034 Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:26 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | Exercise / conversionCommon Stock | 7,601 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-015306 · doc1.xml · nonDerivative · entry 1 Young David · CIK 0001378166 · Director · President & CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Vesting of time-based restricted shares. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 21:33 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 46,877 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-013681 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 349,643 Underlying: Common Stock · 46,877 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| April 01, 2022 Filed Apr 11, 2022 22:00 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 247,841 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-008371 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,766 Underlying: Common Stock · 247,841 shares Expires not disclosed F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan. F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:45 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 10,715 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007980 · doc1.xml · derivative · entry 2 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,781 Underlying: Common Stock · 10,715 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:34 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000307 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,722 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
| December 31, 2021 Filed Jan 6, 2022 22:31 UTC Amendment | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 6,722 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-000782 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,780 Underlying: Common Stock · 6,722 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance. Read SEC document |
| November 01, 2021 Filed Apr 4, 2022 21:45 UTC | Processa Pharmaceuticals, Inc. PCSA · Entity 8210 | GrantRestricted Stock Units · Derivative | 4,286 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-007980 · doc1.xml · derivative · entry 1 Young David · CIK 0001378166 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,066 Underlying: Common Stock · 4,286 shares Expires not disclosed F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.